Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
Top
..
c19early.org COVID-19 treatment researchSelect treatment..Select..
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

Bufei Huoxue for COVID-19

Bufei Huoxue has been reported as potentially beneficial for COVID-19 in the following study. We have not reviewed Bufei Huoxue in detail.
COVID-19 involves the interplay of over 100 viral and host proteins and factors providing many therapeutic targets. Scientists have proposed over 9,000 potential treatments. c19early.org analyzes 130+ treatments.
Hou et al., A Subgroup Reanalysis of the Efficacy of Bufei Huoxue Capsules in Patients With “Long‐Covid‐19”, Pulmonary Circulation, doi:10.1002/pul2.70084
ABSTRACTBufei huoxue capsules (BFHX), manufactured products of traditional Chinese medicine, have demonstrated anti‐inflammatory properties and efficacy against chronic pulmonary diseases and COVID‐19. This study was designed to further determine the clinical efficacy of BFHX in diverse patient subgroups during the convalescent phase of COVID‐19, extending upon previously reported findings from a multicenter randomized controlled trial. Patients who had clinically recovered from COVID‐19 were blindly assigned to BFHX or placebo groups. All enrolled patients underwent chest computed tomography (CT) imaging, 6‐min walking distance (6MWD) test, and fatigue assessment inventory (FAI) at monthly follow‐up for 3 months. A post hoc subgroup reanalysis was performed on subgroups of sex, age, severity of acute illness, and positive/negative IgG antibody against S antigen variants. A total of 129 patients were enrolled in BFHX (N = 64) and placebo groups (N = 65). The 6MWD and FAI scores were more significantly improved in females and mild patients than in males and severe patients after BFHX treatment. Lung CT image evaluated by the change in whole lung volume and mean CT value showed that the patients below 60 years gained more therapeutic effects after 3 months of BFHX treatment (p = 0.0008; p = 0.017; p = 0.0313, respectively). The subgroup reanalysis implies that the therapeutic effectiveness of BFHX in managing COVID‐19 convalescence could potentially be influenced by factors including gender, age, and disease severity.Trial registration: This study was registered with the China Clinical Trial Registration Center (registration number: ChiCTR2000032573).
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit